Longboard Pharmaceuticals Inc LBPH Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$59.98 unchanged at close Dec 2
Last close · Previous close $59.98
- Market cap
- $2.33BAt the Dec 2 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$2.23Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$59.98up $0.29, 0.49%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$59.98Nov 29
- Volume0.00Dec 2 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume825.31KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Dec 2 close. Total return includes reinvested dividends.Price change only, without dividends.
| Period | LBPH |
|---|---|
| Short term | |
| 1M | LBPH: up 0.5% |
| 3M | LBPH: up 66.2% |
| YTD | LBPH: up 894.7% |
| 1Y | LBPH: up 1,399.5% |
| Long term | |
| 3Y | LBPH: up 986.6% +121.5% a year |
$10,000 invested in LBPH a year ago (Dec 1, 2023) would be worth about $149,950 at the close on , with dividends reinvested.
| Period | LBPH |
|---|---|
| Short term | |
| 1M | LBPH: up 0.5% |
| 3M | LBPH: up 66.2% |
| YTD | LBPH: up 894.7% |
| 1Y | LBPH: up 1,399.5% |
| Long term | |
| 3Y | LBPH: up 986.6% +121.5% a year |
$10,000 invested in LBPH a year ago (Dec 1, 2023) would be worth about $149,950 at the close on , not counting dividends.
All-time high
$59.98
Closing high on .
Split-adjusted daily closes since Mar 12, 2021.
Stock splits
LBPH hasn’t split since its price history begins in 2021.
Valuation
The Dec 2 close compared with the last 12 months of reported results (the four quarters to Sep 30, 2024). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$2.23 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 8.5×Book value as of Sep 30, 2024
Price relative to accounting equity (book value) per share on the Sep 30, 2024 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −2.83%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $2.05BAt the Dec 2 close
What it would cost to buy the whole business: the market cap at the Dec 2 close, plus debt, minus cash and short-term investments from the Sep 30, 2024 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own LBPH DCF in Excel. Value Longboard Pharmaceuticals with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY24, the quarter ended Sep 30, 2024. “Last 12 months” means the four quarters from Oct 1, 2023 to Sep 30, 2024, and balance-sheet figures are as of Sep 30, 2024.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$76.34M
- Diluted EPS
- −$2.23
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY22 (Dec 31, 2022) | $0.00 | −$11.35M | −$0.66 |
| Q1 FY23 (Mar 31, 2023) | $0.00 | −$11.46M | −$0.56 |
| Q2 FY23 (Jun 30, 2023) | $0.00 | −$15.00M | −$0.65 |
| Q3 FY23 (Sep 30, 2023) | $0.00 | −$12.93M | −$0.55 |
| Q4 FY23 (Dec 31, 2023) | $0.00 | −$15.03M | −$0.62 |
| Q1 FY24 (Mar 31, 2024) | $0.00 | −$14.99M | −$0.42 |
| Q2 FY24 (Jun 30, 2024) | $0.00 | −$21.79M | −$0.56 |
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$24.54M | −$0.63 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $0.00 | −$14.40M | −$3.78 |
| FY21 (Dec 31, 2021) | $0.00 | −$27.80M | −$1.93 |
| FY22 (Dec 31, 2022) | $0.00 | −$43.95M | −$2.56 |
| FY23 (Dec 31, 2023) | $0.00 | −$54.42M | −$2.39 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$65.93MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$65.93MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $305.11MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $288.45MAs of Sep 30, 2024
Cash plus short- and long-term marketable securities on the Sep 30, 2024 balance sheet.
- Total debt$3.73MAs of Sep 30, 2024
- Net cash$284.71MAs of Sep 30, 2024
- 15.97As of Sep 30, 2024
Current assets divided by current liabilities on the Sep 30, 2024 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.01As of Sep 30, 2024
Total debt divided by shareholders’ equity on the Sep 30, 2024 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −33.0%Last 12 months
Over the last 12 months, Longboard Pharmaceuticals lost money: its net loss was 33.0% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −30.9%Last 12 months
Over the last 12 months, Longboard Pharmaceuticals’s net loss was 30.9% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Longboard Pharmaceuticals Inc
Longboard Pharmaceuticals Inc
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
LBPH news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
LBPH stock FAQ
What is LBPH stock’s price today?
Longboard Pharmaceuticals (LBPH) traded at $59.98 at the close on , unchanged from the previous close of $59.98.
What is Longboard Pharmaceuticals’s market cap?
Longboard Pharmaceuticals’s market capitalization is about $2.3 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $59.98 (how market cap works). Longboard Pharmaceuticals reported 38.90M shares outstanding at the end of its latest quarter ().
What is LBPH’s P/E ratio?
LBPH’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$2.23).
What are LBPH’s earnings per share?
LBPH’s diluted earnings per share were −$2.23 over the four quarters to , compared with −$2.42 in the twelve months before. The latest quarter (Q3 FY24) brought −$0.63 per share, against −$0.55 a year earlier (how EPS works).
Does LBPH pay a dividend?
Longboard Pharmaceuticals hasn’t paid a dividend in the last twelve months.
What is LBPH’s all-time high?
LBPH’s highest closing price was $59.98 on , adjusted for stock splits.
Has LBPH stock ever split?
No. LBPH hasn’t split since its price history begins in 2021.
How has LBPH stock performed?
Including dividends and measured to the close on , LBPH has returned +894.7% so far this year and +1,399.5% over the past year. Past performance doesn’t predict future returns.
What sector and industry is Longboard Pharmaceuticals in?
Longboard Pharmaceuticals is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does LBPH trade on?
Longboard Pharmaceuticals trades on the Nasdaq under the ticker symbol LBPH. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.